SGMC Health is raising the bar in cardiac care with the introduction of a cutting-edge Cardiac Electrophysiology (EP) Lab at ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant ...

Boston Scientific announces favorable study data for its FARAPULSE PFA system and WATCHMAN FLX device at the AF Symposium 2025.

Boston Scientifics FARAPULSE PFA System is approved for pulmonary vein isolation (PVI) in patients who have paroxysmal AF, a ...

Atrial fibrillation (AFib) can affect life expectancy due to factors that include age, underlying health conditions, race, and how this common cardiac arrhythmia—or abnormal heart rhythm— is treated.

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17. In late-breaking data presentations, the ADVANTAGE AF trial for the ...

TD Cowen reiterated a Buy rating for Boston Scientific (NYSE:BSX) stock, maintaining a price target of $110.00. The stock, currently trading at $98.78, has shown remarkable momentum, reaching new ...

With Watchman FLX, a left atrial appendage closure (LAAC) device, Mahoney said the company essentially “created this [LAAC] market over many years.” Boston Scientific reported that Farapulse ...

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field ...